

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **INSIDE INFORMATION**

### **PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (《H股公司境內未上市股份申請“全流通”業務指引》) (the “**Guidelines**”) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019 and further amended on August 10, 2023, regarding the procedures of companies whose H shares are listed on the Stock Exchange for the listing and circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that, on October 25, 2024, the Company has submitted the filing materials with the CSRC in respect of the proposed implementation of H share full circulation (the “**H Share Full Circulation**”), which is to convert an aggregate of 14,114,006 unlisted shares of the Company (the “**Unlisted Shares**”) into H shares of the Company (the “**H Shares**”).

Upon obtaining all relevant approvals (including the filing notice from the CSRC and the approval of the Stock Exchange) and having complied with all applicable laws, regulations and rules, such Unlisted Shares will be converted into H Shares, and the Company will apply for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”). Pursuant to the articles of association of the Company, no further shareholders’ meeting is required to be convened to approve the Conversion and Listing.

As at the date of this announcement, the Company has not completed the filing procedures with the CSRC, and the details of implementation plan of the Conversion and Listing have not been finalised. The Company will make further announcement(s) on the progress and details of the H Share Full Circulation and the Conversion and Listing in compliance with the requirements under Listing Rules and the applicable laws, as and when appropriate.

**The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
**宜明昂科生物醫藥技術(上海)股份有限公司**  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, October 25, 2024

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*